Pulmonx Competitors
| LUNG Stock | USD 1.63 0.01 0.61% |
Pulmonx Corp vs Tela Bio Correlation
Significant diversification
The correlation between Pulmonx Corp and TELA is 0.08 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pulmonx Corp and TELA in the same portfolio, assuming nothing else is changed.
Moving together with Pulmonx Stock
Moving against Pulmonx Stock
| 0.61 | MASI | Masimo | PairCorr |
| 0.47 | BKRKY | Bank Rakyat | PairCorr |
| 0.43 | OTC | Ocumetics Technology Corp | PairCorr |
| 0.42 | CSX | Cleanspace Holdings | PairCorr |
| 0.37 | AHC | Austco Healthcare | PairCorr |
Pulmonx Corp Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pulmonx Corp and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Pulmonx and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pulmonx Corp does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Pulmonx Stock performing well and Pulmonx Corp Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pulmonx Corp's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EDAP | 4.37 | 1.07 | 0.18 | 1.32 | 5.04 | 14.48 | 38.43 | |||
| VXRT | 4.84 | 1.04 | 0.13 | 2.05 | 5.92 | 15.15 | 75.42 | |||
| RLMD | 4.40 | 0.82 | 0.17 | (1.75) | 4.11 | 9.30 | 36.80 | |||
| ACRV | 5.06 | 0.04 | 0.00 | 0.09 | 7.55 | 8.21 | 66.02 | |||
| PMVP | 2.42 | (0.56) | 0.00 | (0.66) | 0.00 | 5.98 | 17.05 | |||
| IMUX | 3.44 | (0.39) | 0.00 | (0.26) | 0.00 | 9.43 | 21.44 | |||
| HYPR | 4.02 | (0.09) | 0.00 | (0.04) | 0.00 | 9.09 | 18.87 | |||
| ASRT | 2.60 | (0.03) | (0.01) | 0.01 | 3.22 | 6.07 | 24.64 | |||
| TCRX | 4.22 | (1.09) | 0.00 | (0.28) | 0.00 | 9.62 | 40.38 | |||
| TELA | 3.03 | (0.52) | 0.00 | (5.94) | 0.00 | 5.38 | 22.82 |
Cross Equities Net Income Analysis
Compare Pulmonx Corp and related stocks such as EDAP TMS SA, Vaxart Inc, and Relmada Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDAP | 181.8 K | (938 K) | (7.5 M) | (5 M) | (512 K) | (1.7 M) | 3.8 M | (681 K) | (338 K) | 1.5 M | (1.7 M) | 700 K | (2.9 M) | (21.2 M) | (19 M) | (17.1 M) | (16.3 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| RLMD | (12.1 K) | (12.1 K) | (12.1 K) | (45 K) | (20.8 M) | (20.8 M) | (3 M) | (6.3 M) | (9 M) | (15 M) | (59.5 M) | (125.8 M) | (157 M) | (98.8 M) | (80 M) | (72 M) | (75.6 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (29.7 M) | (60.4 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| HYPR | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (23.4 M) | (64.8 M) | (73.2 M) | (44.2 M) | (40.7 M) | (36.6 M) | (38.5 M) |
| ASRT | (500 K) | 70.7 M | (29.8 M) | 43.3 M | 131.8 M | (75.7 M) | (88.7 M) | (102.5 M) | 36.9 M | (217.2 M) | (28.1 M) | (1.3 M) | 109.6 M | (331.9 M) | (21.6 M) | (19.4 M) | (20.4 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (127.5 M) | (114.7 M) | (109 M) |
| TELA | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.1 M) | (22.4 M) | (28.8 M) | (33.3 M) | (44.3 M) | (46.7 M) | (37.8 M) | (34.1 M) | (35.8 M) |
Pulmonx Corp and related stocks such as EDAP TMS SA, Vaxart Inc, and Relmada Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Pulmonx Corp financial statement analysis. It represents the amount of money remaining after all of Pulmonx Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Pulmonx Corp Competitive Analysis
The better you understand Pulmonx Corp competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pulmonx Corp's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pulmonx Corp's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Pulmonx Corp Competition Performance Charts
Five steps to successful analysis of Pulmonx Corp Competition
Pulmonx Corp's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pulmonx Corp in relation to its competition. Pulmonx Corp's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Pulmonx Corp in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pulmonx Corp's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pulmonx Corp, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Pulmonx Corp position
In addition to having Pulmonx Corp in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Pulmonx Corp Correlation with its peers. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Can Health Care Equipment & Supplies industry sustain growth momentum? Does Pulmonx have expansion opportunities? Factors like these will boost the valuation of Pulmonx Corp. Expected growth trajectory for Pulmonx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Pulmonx Corp demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.34) | Revenue Per Share | Quarterly Revenue Growth 0.055 | Return On Assets | Return On Equity |
Understanding Pulmonx Corp requires distinguishing between market price and book value, where the latter reflects Pulmonx's accounting equity. The concept of intrinsic value—what Pulmonx Corp's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Pulmonx Corp's price substantially above or below its fundamental value.
Understanding that Pulmonx Corp's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pulmonx Corp represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Pulmonx Corp's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.